Cargando…

SUN-LB091 Impact of Albumin Corrected Calcium on the Prevalence and Categories of Hypercalcemia in Hospitalized Patients

Introduction: Hypercalcemia is a common clinical problem encountered in hospitalized patients. Mild to moderate hypercalcemia diagnoses may be missed during hospitalization since albumin corrected calcium is not automated with laboratory results. Methods: We performed a retrospective study using tot...

Descripción completa

Detalles Bibliográficos
Autores principales: Balasubramanian, Priyadarshini, Majumdar, Sachin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553418/
http://dx.doi.org/10.1210/js.2019-SUN-LB091
_version_ 1783424815629074432
author Balasubramanian, Priyadarshini
Majumdar, Sachin
author_facet Balasubramanian, Priyadarshini
Majumdar, Sachin
author_sort Balasubramanian, Priyadarshini
collection PubMed
description Introduction: Hypercalcemia is a common clinical problem encountered in hospitalized patients. Mild to moderate hypercalcemia diagnoses may be missed during hospitalization since albumin corrected calcium is not automated with laboratory results. Methods: We performed a retrospective study using total and albumin corrected calcium to identify the prevalence and causes of hypercalcemia in hospitalized patients. Patients with corrected calcium ≥ 10.5 mg/dL were identified by searching the electronic medical records of hospital, from June 2012 to June 2017. Albumin-corrected calcium was calculated with the formula [((4-albumin concentration in g/dl) * 0.8) + Total serum calcium in mg/dl] and data were analyzed using SPSS software. Results: From June 2012 to June 2017 there were 97,900 hospital admissions and 711 cases of hypercalcemia based on total calcium, and 1,067 cases based on corrected calcium, resulting in prevalence rates of 0.73% and 1.09%, respectively. Of the 1067 patients, 86% of patients had mild hypercalcemia (10.5-11.9 mg/dL), 10% had moderate hypercalcemia (12-14 mg/dL) and 4% had severe hypercalcemia (>14 mg/dL). When total calcium was considered, malignancy and hyperparathyroidism accounted for the majority of cases representing 48.2% and 28.6% of cases, respectively, followed by the category of other causes (13.2%). When corrected calcium was used the most common categories of hypercalcemia were malignancy (35.4%), hypercalcemia that was not further evaluated (31.1%), and hyperparathyroidism (22.4%). The overall effect of using corrected calcium was a decrease in the proportion of hypercalcemia cases due to malignancy and hyperparathyroidism from 48.2% to 35.4%, and from 28.6 % to 22.4 %, respectively, but an increase in the proportion of unidentified cases from 10% to 31.1%. 31.1% of patients with hypercalcemia were not further evaluated and no identifiable cause was available, resulting in unexplained hypercalcemia being the second most common category. Overall, the majority of hypercalcemia cases were non-malignant. Conclusion: Our major findings are that the use of albumin corrected calcium resulted in a 49% increase in detection of hypercalcemia cases and that the majority of hypercalcemia cases in hospitalized patients are not associated with malignancy. We suggest that increasing the detection of hypercalcemic disorders by correcting for low albumin is worthwhile in order to achieve better estimates of disease prevalence and to detect potentially deleterious conditions in their earlier stages. We propose the implementation of auto calculated albumin corrected calcium to be displayed with routine laboratory results to increase detection of hypercalcemia cases that may be overlooked due to hypoalbuminemia in hospitalized patients. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.
format Online
Article
Text
id pubmed-6553418
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65534182019-06-13 SUN-LB091 Impact of Albumin Corrected Calcium on the Prevalence and Categories of Hypercalcemia in Hospitalized Patients Balasubramanian, Priyadarshini Majumdar, Sachin J Endocr Soc Bone and Mineral Metabolism Introduction: Hypercalcemia is a common clinical problem encountered in hospitalized patients. Mild to moderate hypercalcemia diagnoses may be missed during hospitalization since albumin corrected calcium is not automated with laboratory results. Methods: We performed a retrospective study using total and albumin corrected calcium to identify the prevalence and causes of hypercalcemia in hospitalized patients. Patients with corrected calcium ≥ 10.5 mg/dL were identified by searching the electronic medical records of hospital, from June 2012 to June 2017. Albumin-corrected calcium was calculated with the formula [((4-albumin concentration in g/dl) * 0.8) + Total serum calcium in mg/dl] and data were analyzed using SPSS software. Results: From June 2012 to June 2017 there were 97,900 hospital admissions and 711 cases of hypercalcemia based on total calcium, and 1,067 cases based on corrected calcium, resulting in prevalence rates of 0.73% and 1.09%, respectively. Of the 1067 patients, 86% of patients had mild hypercalcemia (10.5-11.9 mg/dL), 10% had moderate hypercalcemia (12-14 mg/dL) and 4% had severe hypercalcemia (>14 mg/dL). When total calcium was considered, malignancy and hyperparathyroidism accounted for the majority of cases representing 48.2% and 28.6% of cases, respectively, followed by the category of other causes (13.2%). When corrected calcium was used the most common categories of hypercalcemia were malignancy (35.4%), hypercalcemia that was not further evaluated (31.1%), and hyperparathyroidism (22.4%). The overall effect of using corrected calcium was a decrease in the proportion of hypercalcemia cases due to malignancy and hyperparathyroidism from 48.2% to 35.4%, and from 28.6 % to 22.4 %, respectively, but an increase in the proportion of unidentified cases from 10% to 31.1%. 31.1% of patients with hypercalcemia were not further evaluated and no identifiable cause was available, resulting in unexplained hypercalcemia being the second most common category. Overall, the majority of hypercalcemia cases were non-malignant. Conclusion: Our major findings are that the use of albumin corrected calcium resulted in a 49% increase in detection of hypercalcemia cases and that the majority of hypercalcemia cases in hospitalized patients are not associated with malignancy. We suggest that increasing the detection of hypercalcemic disorders by correcting for low albumin is worthwhile in order to achieve better estimates of disease prevalence and to detect potentially deleterious conditions in their earlier stages. We propose the implementation of auto calculated albumin corrected calcium to be displayed with routine laboratory results to increase detection of hypercalcemia cases that may be overlooked due to hypoalbuminemia in hospitalized patients. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO. Endocrine Society 2019-04-30 /pmc/articles/PMC6553418/ http://dx.doi.org/10.1210/js.2019-SUN-LB091 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Bone and Mineral Metabolism
Balasubramanian, Priyadarshini
Majumdar, Sachin
SUN-LB091 Impact of Albumin Corrected Calcium on the Prevalence and Categories of Hypercalcemia in Hospitalized Patients
title SUN-LB091 Impact of Albumin Corrected Calcium on the Prevalence and Categories of Hypercalcemia in Hospitalized Patients
title_full SUN-LB091 Impact of Albumin Corrected Calcium on the Prevalence and Categories of Hypercalcemia in Hospitalized Patients
title_fullStr SUN-LB091 Impact of Albumin Corrected Calcium on the Prevalence and Categories of Hypercalcemia in Hospitalized Patients
title_full_unstemmed SUN-LB091 Impact of Albumin Corrected Calcium on the Prevalence and Categories of Hypercalcemia in Hospitalized Patients
title_short SUN-LB091 Impact of Albumin Corrected Calcium on the Prevalence and Categories of Hypercalcemia in Hospitalized Patients
title_sort sun-lb091 impact of albumin corrected calcium on the prevalence and categories of hypercalcemia in hospitalized patients
topic Bone and Mineral Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553418/
http://dx.doi.org/10.1210/js.2019-SUN-LB091
work_keys_str_mv AT balasubramanianpriyadarshini sunlb091impactofalbumincorrectedcalciumontheprevalenceandcategoriesofhypercalcemiainhospitalizedpatients
AT majumdarsachin sunlb091impactofalbumincorrectedcalciumontheprevalenceandcategoriesofhypercalcemiainhospitalizedpatients